The Science Behind GHK-Cu

This section explains the biology behind GHK-Cu, starting from the basics. GHK is a small tripeptide, made of the amino acids glycine, histidine, and lysine, that binds copper with high affinity. It was first isolated from human plasma in 1973, and researchers have since studied it in cell culture, animal models, and a smaller number of human studies.

The guides here cover how GHK-Cu is thought to work: its role in delivering copper to tissues, its association with collagen and extracellular matrix remodeling, and its reported effects on inflammation and antioxidant signaling. Research has also found that plasma GHK levels are lower in older adults than in younger ones, which is part of why the peptide is studied in the context of aging.

We also review the clinical evidence on safety and efficacy, including where findings are consistent and where larger, well-controlled human trials are still needed. A registered clinical trial of topical GHK-Cu gel for acute skin wounds is ongoing, and no results have been published. Understanding these limits is part of making an informed decision about physician-prescribed therapy.

For specific research takeaways, see GHK-Cu key insights, start with what GHK-Cu is, or see how the science connects to specific GHK-Cu benefits.